Radiation-induced fibrosis is an untoward effect of high dose therapeutic and inadvertent exposure to ionizing radiation. Transforming growth factor beta (TGF-β) has been proposed to be critical in tissue repair mechanisms resulting from radiation injury. Previously, we showed that interruption of TGF-β signaling by deletion of Smad3 results in resistance to radiationinduced injury. In the current study, a small molecular weight molecule, halofuginone (100 nM), is demonstrated by reporter assays to inhibit the TGF-β signaling pathway, by Northern blotting to elevate inhibitory Smad7 expression within 15min, and by Western blotting to inhibit formation of phospho-Smad2 and phospho-Smad3 and to decrease cytosolic and membrane TGF-β type II receptor (TβRII). Attenuation of TβRII levels was noted as early as 
Introduction
Fibrosis is a descriptive appellation referring to obliteration of normal tissue components and replacement by matrix and disordered and varied collagen fibrils with resulting loss of organ function and frequently tissue contraction. Ionizing radiation exposure in sufficiently high dosage applied to any tissue universally evokes loss of cells and fibrosis. At the cellular level, the molecular target that results in radiation-induced death is DNA (1, 2) . At the tissue level, the effects of ionizing radiation are not limited to direct injury and cell death from damage to DNA. Skin has many different cellular components that respond to ionizing radiation in a complex fashion that is reminiscent of an injury response to a wound. Unlike a trauma-induced wound, wherein platelets and other cells from the circulation discharge into the injured tissue and repair is accomplished without fibrosis, high dose radiation-induces cellular damage which results in cytokine and growth factor-mediated signaling that inevitably leads to dysfunctional repair and fibrosis, if not ulceration and necrosis (3) (4) (5) .
Israel. Stock solutions of 1-2 mg/ml were prepared by dissolving crystalline halofuginone in a lactic acid buffer, 0.44M, pH 4.3 and stored at 4°C where it is stable for at least 4 months.
Working solutions for injection of halofuginone (1, 2.5, or 5 µg/0.2ml) were made each day by diluting the stock halofuginone with 0.9% NaCl. The working solution was used within 1h of preparation.
Sodium ortho-vanadate was purchased from Sigma Chemical Company (St. Louis, MO). Stock solution (100 mM) was prepared as described by Gordon (18) and stored at 4 o C.
Okadaic acid was from Calbiochem (San Diego, CA). Stock solution of 1 mM okadaic acid was prepared in DMSO and stored at -70°C. Cycloheximide, 50mg/mL, (Sigma Chemical
Company, St. Louis, MO) was dissolved in ethanol and stored at -20 o C. Actinomycin D, 1mg/mL was dissolved in DMSO and stored at -20 o C.
Animal studies
The animal protocols used in this study were institutionally approved and deemed in accordance with guidelines of the Institute of Laboratory Animal Resources, National Research
Council. C3H/HenNCrMTV-(C3H/Hen) female mice were irradiated between 7-9 weeks after birth. Selective irradiation of the right leg was accomplished by placing each un-anesthetized animal into a specially built Lucite jig that immobilized the animal and facilitated ease of extension of the right hind leg into the radiation field. Lead shields designed as a part of the Lucite jigs assured that only the right hind limb of the immobilized animal was irradiated. A single radiation dose of 35 or 45 Gy was delivered to the right hind leg of the animal by a Page 6 removed from the Lucite jig and housed (5 animals/cage) in a climate and light/dark-controlled environment and allowed free access to food and water.
Each animal received 1, 2.5 or 5 µg/mouse/day halofuginone as an intraperitoneal injection. Ten animals were in each of the 1 and 5 µg/mouse/day treatment groups and 10 animals were in the control vehicle only group. Twenty animals were in each group that received either 35 or 45Gy irradiation and 2.5 µg/day/mouse halofuginone and ten mice for each dose of irradiation received no halofuginone (control). Halofuginone injections were initiated the day before irradiation. Injections of 1 or 5 µg daily was given for 5 months, whereas, 2.5 µg injections were given daily for 3 months. Control animals received vehiclesolution only. Fibrosis as measured by contraction was assessed as previously described (19) .
Briefly, a Lucite jig was made such that an animal's body could be easily positioned within it and extension of the leg could be measured by referring to an inlaid ruler within the base of the jig. The degree of contraction was recorded after extension of the irradiated right hind leg and compared to the extended length of the un-irradiated contra-lateral hind leg. 
Immunoblotting
NMuMg cells, HaCaT cells, COS-7, ANA-1, and MEFs, were grown to 80% confluence, rinsed with PBS, and switched to 0.2% serum overnight. Cells were treated usually with 100 nM halofuginone for varying times and either were not further stimulated or were then stimulated with TGF-β1 (2 ng/ml) for 30 min. Alternatively, cells were plated as described above and treated with 100 nM halofuginone for 4 h followed by stimulation with TGF-β1 (2 ng/ml) for 15, 30, 45 and 60 min. The effect of either tyrosine or serine/threonine phosphatase inhibition on phosphorylated Smad2 and Smad3 was investigated using sodium ortho-vanadate or okadaic acid. Cells were treated with 100 nM halofuginone for 3h, followed by treatment with 1 mM sodium ortho-vanadate for 1h or 100 nM okadaic acid for 1h and then stimulated with TGF-β1 (2 ng/ml) for 15 min. Cells were rinsed with PBS, lysed with lysis hypotonic phosphate buffer and re-centrifuged at 100,000 g x 45 min at 4°C. The pellet was re-dissolved at ambient temperature in hypotonic phosphate buffer containing protease inhibitors, ortho-vanadate, PMSF, and 1% Triton X-100 and then incubated at ambient temperature for 30 min; whereupon it was again centrifuged in an Eppendorf centrifuge at 10,000 rpm x 10 min, 4°C. The supernatant was isolated and the pellet discarded. Protein concentrations were determined according to the manufacturer's protocol (Bio-Rad protein assay kit) and blotted as described above.
For MAPK kinases cytosolic proteins were run on 4-20% gradient SDS-PAGE and transferred to a Protran nitorcellulose membrane (Schleicher & Schuell). After transfer, the Page 13 membrane was washed 3 x 5 min with TBS-T, and blocked overnight with 5% nonfat dry milk (Safeway brand) in TBS-T. Immunoblotting was done with the desired primary antibody at 1:1000 dilution at room temperature for 90 min, washed 4x10 min with TBS-T, immunoblotted with 1:2,000 dilution of an appropriate HRP-coupled secondary antibody, and again washed 4x10 min with TBS-T.
Expression of HA-tagged T RII in COS-7 Cells
COS-7 cells were plated (1.5x10 6 ), 24 h later cells were transfected with 2 µg HAhTβRII, and then 36 h after transfection cells were incubated in 0.2% serum containing medium for12 h, then treated with halofuginone 100 or 200 nM for varying times. Cells were lysed (0.1% SDS, 1% NP-40 in PBS containing phosphatase and protease inhibitors), proteins isolated, and 30 µg total protein was probed using anti-HA antibodies (1:1000). For GST transfection, cells were transfected with 2 µg of hGSTA2.2 cDNA or pCI-neo Vector control as described above. Cells were treated with halofuginone (100 nM) for 8 or 16 h and samples were probed for expression of GSTA2.2 using anti-GST alpha polyclonal antibody (1:2000).
RT-PCR and Northern Blots
Cells were left untreated or treated with halofuginone (100 nM) for 2 h in DMEM with 1% FCS. Total RNA was isolated using an RNeasy kit (Qiagen, Valencia, CA) and RT was performed with 0.5 µg of RNA according to the manufacturer's protocol (Clontech, Advantage RT-for-PCR kit). cDNA was amplified 33 cycles (95°C x 30s; 68°C x 1.5 min; last cycle 68°C extension) using the forward primer 5'-GGTTTACAACCGCAGTTACCC-3, and the reverse primer CTGATCTGCACGGTGAAACCCGTC-3' using Titanium Taq PCR kit (Clontech, Palo Alto, CA). PCR product was electrophoresed on agarose, stained, and visualized with Gel Doc system (Biorad, Hercules, CA). Cells were grown to 80% confluency in DMEM with 10% µg/ml) or cyclohexamide (final concentration 10 µg/ml) was added for 1h, followed by addition of halofuginone (100 nM). Total RNA was isolated at various times after addition of halofuginone. The desired Smad7 fragment was removed from pcDNA3 by EcoRI/ XhoI endonuclease restriction, isolated, and labeled with (α-32 P) dCTP.
Statistics
Means and standard error of the mean were calculated. Significance was analyzed using a two-tailed Student's t-test.
Results

Halofuginone Inhibits Activation of TGF-dependent Reporters
The effects of halofuginone on TGF-β signaling were examined using SBE4-luc containing 4 CAGA Smad binding elements (SBE) activated by Smad3/4 complexes (28) . As is seen in Figures 1a and 1b , halofuginone inhibited TGF−β1 induced signaling. Halofuginone 
Halofuginone Inhibits TGF-dependent Phosphorylation of Smad2 and Smad3
Since the TGF−β1 signaling pathway as assessed by the above reporters can be interrupted at many sites, we sought to determine whether Smad3 or Smad2 phosphorylation was inhibited, and if so, whether the inhibition is cell-type specific. The effects of halofuginone on TGF−β1 activation of the Smad 2/3 pathway were determined at three different time points in three different cell types--murine mammary gland epithelial cells (NMuMg), a human keratinocyte cell line (HaCaT), and mouse embryo fibroblasts (MEF). 
Halofuginone Reduces Levels of T RII Post-translationally
We next investigated whether halofuginone could regulate TβRI or TβRII. Down regulation of either would suppress Smad2/3 phosphorylation. Figure 3a shows the level of 
Halofuginone Induces Expression of the mRNA for the Signaling Inhibitor Smad7
Although decreasing TβRII would be sufficient to account for the molecular action of halofuginone, we investigated whether another mechanism could contributed to the down regulation of phospho-Smad2/3. Smad7 is an inhibitory peptide well recognized to inhibit http://www.jbc.org/ process (38) . Therefore to assess if halofuginone could inhibit the transdifferentiating effect of TGF-β on NMuMg cells ZO-1 function was assessed. TGF-β is known to induce delocalization of inter-cellular ZO-1. Figure 5 shows ZO-1 within the tight junction. Figure 5 shows that TGF-β induces the delocalization of ZO-1 from the tight junction and also shows that halofuginone inhibits TGF-β-induced delocalization, i.e. , TGF-β-induced transdifferentiating effect is inhibited.
Halofuginone Decreases In vivo Radiation-induced Contraction of Limbs
Based on our previous demonstrations that Smad3 null mice were more resistant to ionizing radiation and the current finding that halofuginone down regulates phospho-Smad3 by mechanisms likely involving both suppression of TβRII and induction of expression of Smad7, we asked whether halofuginone would be useful in ameliorating radiation injury/fibrosis in a mouse. One of us (S.Y.) had previously investigated halofuginone pharmacology and determined the non-toxic doses of halofuginone to be used in this study. Since radiation injury results in a highly complex biologic response, we investigated the efficacy of halofuginone by using the functional post-irradiation leg contraction assay (19) . In this assay the extent of contraction of the irradiated leg is compared to the contra-lateral leg in the same animal, hence each animal is its own control. Three cohorts of 10 mice were irradiated with a single dose of 35 Gy. The control group received no halofuginone and the other two groups received either 1 or 5 µg/day halofuginone as an intraperitoneal injection for 5 months. The animals were followed for several months after halofuginone treatment was discontinued. Figure 6a shows that halofuginone decreased radiation-induced contraction, a surrogate for fibrosis. In this model, contraction rarely exceed 30%, i.e. the irradiated leg does not contract to a size less than 70% of the contra-lateral, un-irradiated leg. Legs of the control group, which received 35
Gy and no halofuginone, extended to 70-80% of the un-irradiated contra-lateral leg; whereas, legs of halofuginone treated animals extended on average over the study period to approximately 90% of control levels (p = <0.01 for all time points at both doses of halofuginone). Additionally, there was a suggestion of a dose response to halofuginone.
Animals that received 5µg/day halofuginone on average had less leg contraction when compared to the 1µg/day group. We subsequently assessed an intermediate dose of halofuginone (2.5µg/day) given as a daily injection for a shorter time after irradiation (3 months), and we also used different doses of radiation (35 Gy and 45 Gy, 20 mice per group). Oftentimes radiation-induced fibrosis occurs as an untoward effect of treating a malignant tumor. To lessen fibrosis by the use of halofuginone and also lessen the effect of radiation would be self-defeating. Therefore, halofuginone was administered each day during daily-fractionated (200 cGy/day/x5) radiation treatment of a SCC, squamous cell carcinoma, grown in C3H/Hen mice. The effect of co-administration of halofuginone was evaluated by assessing impact on re-growth delay. The re-growth delay assay is a standard means of determining if an agent or modality lessens or enhances the effect of ionizing radiation (39, 40) . Figure 7 illustrates that halofuginone does not lessen the therapeutic effect of ionizing radiation on SCC tumor.
Discussion
Previously, halofuginone was shown to decrease thioacetamide-induced liver fibrosis (17) , to lessen graft versus host disease (41) , and to lessen mesangial cell proliferation and matrix deposition in the kidney (42) . We show in the current study that halofuginone induces expression of the inhibitory Smad7 and decreases TβRII levels, which decreased activation of Smad2 and Smad3 and hence inhibition of TGF-β signaling through the Smad pathway. Our previous work with Smad3 null animals showing them to be more resistant to radiation (13) and our findings reported here that halofuginone reduced signaling through the Smad pathway, led us to successfully employ halofuginone as a small molecular weight compound to lessen ionizing radiation-induced leg contraction.
While the current study was underway, McGaha et al. showed in fibroblasts from a tight skin mouse (model of scleroderma) that halofuginone inhibited TGF-β induced activation of Smad3 (43) . The tight skin mouse model addresses an autoimmune process and does not necessarily relate to radiation-induced fibrosis. In the study of McGaha, neither inhibition of phosphoSmad2, nor up-regulation of Smad7, nor down-regulation of TβRII was noted. The differences probably reflect 1.) different fibrogenic etiologies; 2.) different dosages of halofuginone utilized, and 3.) different cell lines employed. We used multiple cell types in our study: NMuMg (mammary epithelial), HaCAT (keratinocyte), HepG2 (hepatocellular carcinoma), ANA-1 (macrophage), and fibroblasts: MEF, COS-7, NEMO/IKK, KO-JNK, and Smad3 wild type and null dermal fibroblasts and showed the effects of halofuginone to be similar.
Up regulation of TβRII in irradiated tissue has been previously reported (44) .
Interestingly, fibroblast-specific TβRII-kinase deficient mice were recently shown to paradoxically have increased fibrosis (45) . This finding would appear to be in conflict with the results reported here in which halofuginone treatment resulted in a decrease in TβRII levels and Smad2/3 signaling, and decreased fibrosis. However, in the fibroblast-specific, kinasedeficient TβRII animal, there is a paradoxical increase in intracellular TGF-β-dependent signaling, as a result of the transgenic expressing a dominant negative TβRII rather than a null allele within the fibroblast. The consequence of increased signaling through the TGF-β pathway resulting in increased in vivo fibrosis supports our finding in which down regulation of TβRII by halofuginone reduces radiation-induced fibrosis.
Halofuginone specifically decreased levels of TβRII; levels of TβRI were not affected by halofuginone treatment (Figure 3a) . Down regulation of the TβRII receptor by halofuginone was noted as early as 1 h (Figure 3c-2) , and the receptor was practically undetectable by 4-8 h (Figure 3c-3) . Using Western blotting we found TβRII to decrease quickly with a half-life of approximately 2 h (Figure 3c-2) . This finding agrees well with previous findings using pulse chase that showed TβRII to have half-life of approximately 2 1/2 h (46).
The effect of halofuginone on Smad7 up regulation was shown to be independent of NFκB and JNK and Smad3 signaling (Figure 4 ). In the context of fibrosis, fibroblasts are the cells responsible for deposition of matrix. We showed that halofuginone up regulates Smad7 in multiple fibroblast cell lines. It was recently reported that in a rat liver model of fibrosis increased expression of the inhibitory Smad7 resulted in decreased collagen synthesis, down regulation of TGF-β signal transduction, decreased phospho-Smad2 and Smad3, and decreased transdifferentiation of hepatic stellate cells, all of which resulted in less fibrogenesis (47) . In the current study, the up regulation of Smad7 may similarly contribute to the anti-fibrosis noted in vivo.
Of the many biologic responses to TGF-β, induction of EMT transition has been shown by Iwano et al. (38) to be associated with the fibrogenic response. Were halofuginone to function as an inhibitor of radiation-induced fibrosis, halofuginone should inhibit TGF-β induced EMT. Figure 5 illustrates clearly that halofuginone does act to inhibit TGF-β induced delocalization of tight junction associated ZO-1. Since delocalization of ZO-1 is associated with EMT, the finding that halofuginone inhibits TGF-β-induced ZO-1 delocalization strengthen the premise that halofuginone could function as an anti-fibrogenesis agent.
In our previous study we showed that mice with a targeted deletion in the Smad3 gene (Smad3 ex8/ex8 ) were less susceptible to radiation-induced injury when compared to their correspondingly irradiated wild-type littermates (13) . We were unable to protract the study to investigate chronic radiation-induced fibrosis because of the reduced lifespan of these mice.
However, using halofuginone in a normal, non-mutated C3H/Hen mice has allowed for more protracted studies to determine if halofuginone would ameliorate radiation-induced fibrosis.
Since radiation-induced fibrosis is a complex biologic phenomenon, we assessed its onset and severity by using a functional endpoint, radiation-induced contraction, which is a better reflection of the untoward effect of radiation injury in solid tissue than a typically measured surrogate endpoint of fibrosis such as collagen deposition. The radiation-induced pulmonary fibrosis model is frequently used to evaluate radiation fibrosis, but we chose to use experimental conditions that represented solid tissue damage and was amenable to ready assessment and reproducible quantitative analyses. The leg contraction model is a particularly demanding model because the agent being tested to lessen contraction must have an effect on a complex set of biologic events. Although there are many possible dosing schedules, the regimens we employed demonstrated that halofuginone lessened contraction ( Figure 6 ). Just as important, halofuginone did not interfere with the therapeutic effect of radiation on squamous cell carcinoma ( Figure 7) . Even though the results were not statistically significant, halofuginone plus radiation lengthened the re-growth time of the tumor, which signifies minimally that there was no adverse treatment effect associated with using halofuginone when treating a growing tumor.
Evidence of the importance of Smad3 in mediating fibrogenic signaling from TGF-β continues to accrue. Zhao et al. showed that mice deficient in Smad3 experience less lung fibrosis as a result of bleomycin toxicity (48) . Both the early radiation-induced injury to the skin (49) and bleomycin-induced lung fibrosis (48, 49) are blocked in the absence of Smad3, as is synthesis of type I collagen following carbon tetrachloride-induced liver injury (50) .
Moreover, studies in human dermal fibroblasts have shown that extracellular matrix proteinrelated genes induced by TGF-β, including several collagens and the tissue inhibitor of metalloproteinases-1 (TIMP-1), are, in part, Smad3 dependent (51) . Global analysis of the transcriptome in mouse embryo fibroblasts shows that over 95% of the TGF-β-dependent transcriptional effects in these cells are Smad3-dependent (52) . The ability of halofuginone to attenuate radiation-induced fibrosis is consistent with its ability to block TGF-β function through Smad3.
We are aware that TGF−β1 is not the only bio-molecule that may be mediating the tissue response to ionizing radiation (6, 53, 54) . Nor is the Smad pathway the sole pathway mediating effects of TGF-β on cells (55-57). We investigated whether MAPK signaling as evaluated by activation of p38, JNK, MAPK changed as a result of halofuginone treatment and found that it was unaffected (data not shown). Although TGF−β signaling through Smad pathways is not solely responsible for radiation-induced fibrosis, the current results show that this pathway has an important function in radiation-induced fibrosis.
In summary, we demonstrate that the anti-fibrotic agent, halofuginone, interferes with TGF-β signaling by inhibiting Smad2/3 activation through at least two distinct mechanisms, including down-regulation of the levels of TβRII and induction of the inhibitory Smad, Smad7.
Most importantly, our results show that halofuginone can be administered safely for long NMuMg cells were treated with halofuginone (100nM) for 4h, followed by treatment with TGF-β1 for 1h and nuclear fractions were isolated. Cells were treated with halofuginone (100 nM) for 3 h followed by sodium ortho-vanadate (1mM) (e) or okadaic acid (100nM) (f) for 1h.
TGF-β1 was added and cells were lysed after 15 min. Protein were separated on a 4-20% SDS-PAGE gel and the blots probed with anti-pSmad2, anti-pSmad3 or anti-Smad2/3. 
